¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå - Á¦Ç° À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«) : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)
Cell-free Fetal DNA Testing Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030
»óǰÄÚµå : 1454796
¸®¼­Ä¡»ç : Persistence Market Research
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 267 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 6,977,000
Unprintable PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ º¹»ç, ÀμⰡ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,295 £Ü 10,190,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 11,866,000
PDF & Excel (Corporate User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Persistence Market Research´Â ÃÖ±Ù ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå¿¡ ´ëÇÑ ½ÉÃþ ºÐ¼®À» ½Ç½ÃÇÏ¿© ¼¼°è »óȲ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ º¸°í¼­¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ º¸°í¼­´Â ½ÃÀå ¿ªÇÐ, µ¿Çâ, ±âȸ ¹× °úÁ¦¿¡ ´ëÇÑ ÁÖ¿ä ÀλçÀÌÆ®¸¦ Á¦°øÇÏ°í ½ÃÀå ±¸Á¶¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ °³¿ä¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â 2023³âºÎÅÍ 2030³â±îÁö ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀåÀÇ ¿¹Ãø ¼ºÀå ±ËÀûÀ» ¿¹ÃøÇÏ°í µ¶ÀÚÀûÀÎ µ¥ÀÌÅÍ¿Í Åë°è¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀåÀº ¿¬Æò±Õ 10%ÀÇ ¼ºÀå·üÀ» º¸À̸ç 2023³â 15¾ï ´Þ·¯¿¡¼­ 2030³â 29¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå - Á¶»ç ¹üÀ§

¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç(cffDNA)·Î ¾Ë·ÁÁø Çõ½ÅÀûÀÎ »êÀü ¼±º° °Ë»ç´Â »ê¸ðÀÇ Ç÷¾×¿¡ Á¸ÀçÇÏ´Â ÅÂ¾Æ DNA Á¶°¢À» °Ë»çÇÏ¿© žÆÀÇ À¯ÀüÀÚ ºÐ¼®¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ ±â¼úÀº ¾ç¼ö õÀÚ¿Í °°Àº ħ½ÀÀû ½Ã¼úÀÌ ÇÊ¿ä ¾ø°í, À§Çè ¾øÀÌ Áß¿äÇÑ À¯ÀüÀû ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖÀ¸¸ç, ƯÈ÷ ´Ù¿îÁõÈıº°ú °°Àº ¿°»öü ÀÌ»ó ¹ß°ß¿¡ ÀÖ¾î žÆÀÇ °Ç°­ »óŸ¦ º¸´Ù ¾ÈÀüÇÏ°Ô Æò°¡ÇÒ ¼ö ÀÖ´Â ¼ö´ÜÀ» º¸ÀåÇÕ´Ï´Ù.

»êÀü Áø´ÜÀÇ ¿ªµ¿ÀûÀÎ »óȲ ¼Ó¿¡¼­ cffDNA °Ë»ç ½ÃÀåÀº Å« ÆøÀÇ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î´Â ´ëÁßÀÇ ÀÎ½Ä Áõ°¡, ±â¼ú ¹ßÀü, Á¶±â ºñħ½ÀÀû »êÀü °ËÁø¿¡ ´ëÇÑ °ü½É µîÀÌ ÀÖ½À´Ï´Ù. Á¤È®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â »êÀü À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÀÌ·¯ÇÑ ¼ºÀå ±Ëµµ¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ±× °á°ú, Àü ¼¼°è ÀÓ»êºÎµéÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¸¦ ÃæÁ·½Ãų ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ºñÁî´Ï½º ±âȸ°¡ âÃâµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

À¯Àüü ±â¼ú, ƯÈ÷ Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)ÀÇ ¹ßÀüÀº ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, NGS´Â Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½ÃÄÑ ´õ ¸¹Àº ÀÓ»êºÎ¿¡°Ô °Ë»ç¸¦ ½ÃÇàÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. »ê¸ð ¿¬·ÉÀÇ Áõ°¡¿Í »êÀü °ËÁø ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Á¶±â Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â »êÀü Áø´Ü ½ÃÀåÀÇ ¼ºÀå°ú ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¾ïÁ¦¿äÀÎ

¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»çÀÇ »ó¾÷Àû È®´ë´Â Å« ÁøÀü¿¡µµ ºÒ±¸Çϰí, ±ÔÁ¦¿Í À±¸®Àû °í·Á»çÇ×À¸·Î ÀÎÇØ Å« Á¦¾àÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¾÷°è ÀÌÇØ°ü°èÀÚµéÀº ÀÌ·¯ÇÑ °Ë»çÀÇ Á¤È®¼º°ú ½Å·Ú¼ºÀ» º¸ÀåÇϱâ À§ÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í À¯ÀüÀÚ Á¤º¸ÀÇ ¾Ç¿ë °¡´É¼º¿¡ ´ëÇÑ À±¸®Àû ¿ì·Á·Î ÀÎÇØ Àå¾Ö¹°¿¡ ºÎµúÈ÷°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ±â¼úÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú º¸±ÞÀ» ÃËÁøÇϱâ À§Çؼ­´Â º¹ÀâÇÑ ±ÔÁ¦ »óȲÀ» ±Øº¹ÇÏ°í »êÀü À¯ÀüÀÚ °Ë»ç¿Í °ü·ÃµÈ À±¸®Àû µô·¹¸¶¸¦ ÇØ°áÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.

½ÃÀå ±âȸ

¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»çÀÇ Àü ¼¼°è È®´ë´Â ¾÷°è¿¡ À¯¸ÁÇÑ ±âȸÀÔ´Ï´Ù. ±×·¯³ª ±ÔÁ¦ Áؼö¿Í À±¸®Àû ¹®Á¦·Î ÀÎÇÑ µµÀü°úÁ¦µµ ³²¾ÆÀÖ½À´Ï´Ù. Áö¿ª ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿ÍÀÇ ÆÄÆ®³Ê½Ê°ú ¹®È­Àû ÀûÀÀ¼ºÀ» Æ÷ÇÔÇÑ È¿°úÀûÀÎ ½ÃÀå ħÅõ Àü·«ÀÌ ¼º°øÀÇ ¿­¼è´Ù. Á¾ÇÕÀûÀÎ ¿©¼º °Ç°­ ÇÁ·Î±×·¥°ú °áÇÕµÈ »êÀü À¯ÀüÇÐ °Ë»ç´Â ȯÀÚÀÇ °á°ú¿Í Ä¡·á Á¢±Ù¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ °Ë»ç ±â¼ú¿¡ ´ëÇÑ °øÆòÇÑ Á¢±ÙÀ» º¸ÀåÇϱâ À§ÇØ ÇØ°áÇØ¾ß ÇÒ Àå¾Ö¹°·Î ±³À° °ÝÂ÷¿Í Á¢±Ù¼º °ÝÂ÷°¡ ¿©ÀüÈ÷ ³²¾Æ ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ¼¼°èÀÇ ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦4Àå ¼¼°èÀÇ ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå Àü¸Á : Áö¿ª

Á¦5Àå ºÏ¹ÌÀÇ ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦6Àå À¯·´ÀÇ ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦7Àå µ¿¾Æ½Ã¾ÆÀÇ ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦8Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦9Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹«¼¼Æ÷ ÅÂ¾Æ DNA °Ë»ç ½ÃÀå Àü¸Á : ½ÇÀû(2018-2022³â)°ú ¿¹Ãø(2023-2030³â)

Á¦11Àå °æÀï »óȲ

Á¦12Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Persistence Market Research has recently conducted an in-depth analysis of the Cell-free Fetal DNA Testing Market, providing a comprehensive report on the global landscape. This report offers key insights into market dynamics, trends, opportunities, and challenges, offering a detailed overview of the market structure. The research publication presents exclusive data and statistics, projecting the anticipated growth trajectory of the Cell-free Fetal DNA Testing Market from 2023 to 2030.

The worldwide market for cell-free fetal DNA testing is projected to grow at a compound annual growth rate (CAGR) of 10%, reaching a valuation of US$2.9 billion by 2030, up from US$1.5 billion in 2023.

Key Insights:

Cell-free Fetal DNA Testing Market - Report Scope

Innovative prenatal screening, known as cell-free fetal DNA testing (cffDNA), revolutionizes genetic analysis of unborn babies by examining fetal DNA fragments present in the mother's blood. This technique eliminates the need for invasive procedures like amniocentesis, providing crucial genetic insights without risks. CffDNA testing ensures a safer means of assessing fetal health, particularly in detecting chromosomal abnormalities such as Down syndrome.

Amidst the dynamic landscape of prenatal diagnostics, the market for cffDNA testing is witnessing substantial growth. Factors driving this expansion include heightened public awareness, advancements in technology, and a focus on early, non-invasive prenatal screening. The rising demand for accurate and reliable prenatal genetic testing fuels this growth trajectory. Consequently, there arises an opportunity for businesses to innovate and cater to the evolving needs of expectant parents worldwide.

Market Growth Drivers

Advancements in genomic technologies, particularly next-generation sequencing (NGS), are driving growth in the cell-free fetal DNA testing market. NGS enhances accuracy and efficiency, making it feasible for a broader range of expectant parents. Factors such as increasing maternal age and greater awareness of prenatal screening options further contribute to market expansion. The demand for non-invasive, early detection methods continues to grow, stimulating both market growth and technological innovation in prenatal diagnostics.

Market Restraints

Despite significant progress, the commercial expansion of cell-free fetal DNA testing is significantly impeded by regulatory challenges and ethical considerations. Industry stakeholders encounter hurdles due to stringent regulations aimed at ensuring the accuracy and reliability of these tests, as well as ethical concerns regarding the potential misuse of genetic information. To foster the continued growth and widespread adoption of these advanced technologies, navigating complex regulatory landscapes and addressing ethical dilemmas associated with prenatal genetic testing will be imperative.

Opportunities

Global expansion of cell-free fetal DNA testing presents a promising opportunity for the industry. However, challenges persist due to regulatory compliance and ethical concerns. Effective market penetration strategies, including partnerships with regional healthcare providers and cultural adaptability, are crucial for success. Combining prenatal genetic testing with comprehensive women's health programs can enhance patient outcomes and access to care. Educational gaps and disparities in accessibility remain obstacles that need to be addressed to ensure equitable access to these innovative screening technologies.

Key Questions Answered in Report::

Competitive Intelligence and Business Strategy

The market for cell-free fetal DNA testing is fiercely competitive, with established giants like Sequenom Laboratories and newcomers like Apollo Path Labs vying for dominance. Strategic partnerships, robust R&D, and mergers and acquisitions drive innovation and market share expansion. Emerging specialty firms contribute to diversity and innovation, challenging established players and fueling healthy competition. Dynamic market dynamics and technological advancements shape the competitive landscape, offering both opportunities and challenges for industry participants.

Key Companies Profiled

Cell-free Fetal DNA Testing Market Segmentation

By Test Type:

By Region:

Table of Contents

1. Executive Summary

2. Market Overview

3. Global Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

4. Global Cell-free Fetal DNA Testing Market Outlook: Region

5. North America Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

6. Europe Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

7. East Asia Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

8. South Asia & Oceania Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

9. Latin America Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

10. Middle East & Africa Cell-free Fetal DNA Testing Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

11. Competition Landscape

12. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â